GERON CORP Lessee, Operating Lease, Liability, Undiscounted Excess Amount
GERON CORP (GERN) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $1.74 million as of 2021-06-30, per its 10-Q filed 2021-08-16.
Discontinued › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2021-08-16
- 2021-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1.74M.
- 2021-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1.84M.
- 2020-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1.94M.
- 2020-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2.05M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2021-06-30 | $1.74M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $1.84M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $1.94M 10-K · filed 2021-03-11 |
| 2020-09-30 | $2.05M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $2.22M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $2.27M 10-Q · filed 2020-05-28 |
| 2019-12-31 | $1.29M 10-K · filed 2020-03-12 |
| 2019-03-31 | $12.00K 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |